In this episode of OncoDaily, Dr. Benjamin Maughan, genitourinary oncologist at Huntsman Cancer Center, discusses his research on PSA dynamics in metastatic castration-sensitive prostate cancer. Using real-world data, Dr. Maughan explores how early PSA responses to ADT and apalutamide predict overall survival. The study confirms that achieving an undetectable PSA within three months is a strong indicator of better survival outcomes. Tune in to learn how these findings align with clinical trial results and highlight the effectiveness of ADT-apalutamide therapy.
@HuntsmanCancerInstitute

Abstract:- [ Ссылка ]

#Oncology #Cancer #OncoDaily #ProstateCancer #GenitourinaryOncology ##PSADynamics #MetastaticCastration #RealWorldData #PSAResponse #ADT #Apalutamide #CancerResearch #SurvivalOutcomes #ProstateCancerResearch #HuntsmanCancerCenter #CancerTreatment #ClinicalTrials

SUBSCRIBE to get the latest #oncodaily [ Ссылка ]

Visit the OncoDaily Website : [ Ссылка ]
Like OncoDaily on LinkedIn: [ Ссылка ]
Like OncoDaily on X (Twitter): [ Ссылка ]
Follow OncoDaily on Instagram: [ Ссылка ]
Follow OncoDaily on TikTok: [ Ссылка ]
Like OncoDaily on Facebook: [ Ссылка ]

SUBSCRIBE to OncoDaily Newsletter: [ Ссылка ]

About OncoDaily
OncoDaily is a world-leading oncology media platform, which is based in the United States and features the cancer related latest news, insights, and patient stories from around the globe. The mission of OncoDaily is to empower patients, survivors, and professionals with the knowledge and inspiration they need to fight cancer. The motto of OncoDaily is “Cancer doesn’t take a day off – neither do we.”

свернуть